In conversation with... James Nagarajah

from Listen to The Lancet Oncology · host The Lancet

Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE).

Episode metadata supplied by the publisher feed · Published Mar 31, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... James Nagarajah

0:00 10:55

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 10 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on March 31, 2026.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!